PL360368A1 - Leczenie zaburzeń czynności moczowych - Google Patents

Leczenie zaburzeń czynności moczowych

Info

Publication number
PL360368A1
PL360368A1 PL01360368A PL36036801A PL360368A1 PL 360368 A1 PL360368 A1 PL 360368A1 PL 01360368 A PL01360368 A PL 01360368A PL 36036801 A PL36036801 A PL 36036801A PL 360368 A1 PL360368 A1 PL 360368A1
Authority
PL
Poland
Prior art keywords
treatment
urinary dysfunction
urinary
dysfunction
Prior art date
Application number
PL01360368A
Other languages
English (en)
Inventor
Julian Alexander Barden
Angus Gidley-Baird
Original Assignee
Intreat Pty Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intreat Pty Limited filed Critical Intreat Pty Limited
Publication of PL360368A1 publication Critical patent/PL360368A1/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
PL01360368A 2000-08-28 2001-08-28 Leczenie zaburzeń czynności moczowych PL360368A1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPQ9687A AUPQ968700A0 (en) 2000-08-28 2000-08-28 Treatment of urinary incontinence
PCT/AU2001/001079 WO2002017929A1 (en) 2000-08-28 2001-08-28 Treatment of urinary dysfunction

Publications (1)

Publication Number Publication Date
PL360368A1 true PL360368A1 (pl) 2004-09-06

Family

ID=3823741

Family Applications (1)

Application Number Title Priority Date Filing Date
PL01360368A PL360368A1 (pl) 2000-08-28 2001-08-28 Leczenie zaburzeń czynności moczowych

Country Status (19)

Country Link
US (1) US20040067967A1 (pl)
EP (1) EP1315503A4 (pl)
JP (1) JP2004506744A (pl)
KR (1) KR20030034162A (pl)
CN (2) CN1479621A (pl)
AU (1) AUPQ968700A0 (pl)
BR (1) BR0113667A (pl)
CA (1) CA2420846A1 (pl)
CZ (1) CZ2003807A3 (pl)
EA (1) EA007092B1 (pl)
EE (1) EE200300082A (pl)
HU (1) HUP0300860A3 (pl)
IL (1) IL154642A0 (pl)
MX (1) MXPA03001833A (pl)
NO (1) NO20030978L (pl)
NZ (1) NZ537643A (pl)
PL (1) PL360368A1 (pl)
WO (1) WO2002017929A1 (pl)
ZA (1) ZA200302340B (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030148394A1 (en) * 2002-01-18 2003-08-07 Millennium Pharmaceuticals, Inc. Methods and compositions for treating urological disorders using 1435, 559, 34021, 44099, 25278, 641, 260, 55089, 21407, 42032, 46656, 62553, 302, 323, 12303, 985, 13237, 13601, 18926, 318, 2058, or 6351 molecules
US20050143323A1 (en) * 2003-12-30 2005-06-30 Henley E. C. Isoflavone therapy for treating urinary incontinence
KR100462173B1 (ko) * 2004-06-08 2004-12-16 안국약품 주식회사 요실금 예방 및 치료용 조성물
US20060039971A1 (en) * 2004-08-19 2006-02-23 Lee Robert E Effervescent composition including alternative hormone replacement therapy agent
ATE537169T1 (de) * 2005-08-15 2011-12-15 Hoffmann La Roche Piperidin- und piperazinderivate als p2x3- antagonisten
KR20090029237A (ko) 2006-06-02 2009-03-20 피어 트리 파머슈티칼스 인코포레이티드 위축성 질염을 치료하는 방법
JP5128603B2 (ja) * 2006-10-04 2013-01-23 エフ.ホフマン−ラ ロシュ アーゲー フェノキシジアミノピリミジン誘導体の合成方法
US8277426B2 (en) 2009-09-30 2012-10-02 Wilcox Heather J Male urinary incontinence device
AU2016318230B2 (en) 2015-09-11 2020-05-21 Biosceptre (Aust) Pty Ltd Chimeric antigen receptors and uses thereof
CN109862883A (zh) 2016-10-21 2019-06-07 生物权威(英国)有限公司 细胞毒性颗粒
MX2022003983A (es) * 2019-10-02 2022-04-26 Aska Pharm Co Ltd Agente mejorador de los trastornos de la miccion.
WO2021065027A1 (ja) * 2019-10-02 2021-04-08 あすか製薬株式会社 排尿障害改善剤

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10501122A (ja) * 1994-05-27 1998-02-03 グラクソ、グループ、リミテッド P▲下2x▼レセプター(プリノセプターファミリー)
US6262115B1 (en) * 1995-05-22 2001-07-17 Alza Coporation Method for the management of incontinence
US5861431A (en) * 1995-06-07 1999-01-19 Iotek, Inc. Incontinence treatment
US5789442A (en) * 1996-01-18 1998-08-04 Schering Aktiengesellschaft Treatment of urinary incontinence with nitric oxide synthase substrates and/or nitric oxide donors alone or in combination with estrogen or progesterone and/or other agents
AUPO203996A0 (en) * 1996-08-30 1996-09-26 Novogen Research Pty Ltd Therapeutic uses
US5856129A (en) * 1996-10-30 1999-01-05 Incyte Pharmaceuticals, Inc. DNA encoding a human purinoceptor

Also Published As

Publication number Publication date
KR20030034162A (ko) 2003-05-01
NO20030978L (no) 2003-04-16
EA200300264A1 (ru) 2003-10-30
HUP0300860A3 (en) 2005-03-29
US20040067967A1 (en) 2004-04-08
EE200300082A (et) 2004-12-15
CA2420846A1 (en) 2002-03-07
NZ537643A (en) 2006-04-28
MXPA03001833A (es) 2004-11-01
NO20030978D0 (no) 2003-02-28
CN1479621A (zh) 2004-03-03
ZA200302340B (en) 2004-06-28
WO2002017929A1 (en) 2002-03-07
EA007092B1 (ru) 2006-06-30
HUP0300860A2 (hu) 2003-11-28
CZ2003807A3 (cs) 2003-08-13
AUPQ968700A0 (en) 2000-09-21
JP2004506744A (ja) 2004-03-04
EP1315503A1 (en) 2003-06-04
IL154642A0 (en) 2003-09-17
EP1315503A4 (en) 2005-02-09
BR0113667A (pt) 2003-06-03
CN101164541A (zh) 2008-04-23

Similar Documents

Publication Publication Date Title
GB0007193D0 (en) Treatment of movrmrnt disorders
IL153492A0 (en) Treatment of male sexual dysfunction
GB0014969D0 (en) Novel method of treatment
AU5040101A (en) Improved treatment of neovascularization
IL154642A0 (en) Treatment of urinary dysfunction
HUP0302430A3 (en) Use of 1-phenyl-3-dimethylaminopropane compounds for treating urinary incontience
HRP20020729A2 (en) Treatment of psoriasis
IL155775A0 (en) Treatment of male sexual dysfunction
PL362980A1 (pl) Sposób leczenia dysfunkcji seksualnej
GB0008921D0 (en) Method of treatment
AU8160701A (en) Treatment of urinary dysfunction
EP1303281A4 (en) METHODS OF TREATMENT
AU2001281607A1 (en) Treatment of urinary dysfunction
AU1079402A (en) Wastewater treatment
GB0025655D0 (en) Sludge treatment
GB0011926D0 (en) Treatment of sexual dysfunction
GB0127006D0 (en) Treatment of moccasion seam
AU6191201A (en) Treatment of effluent
GB0014904D0 (en) Methods of treatment
GB0013928D0 (en) Methods of treatment
TW417741U (en) Improved structure of faucet body
GB0017952D0 (en) Treatment of dyskinesia
AU2002219247A1 (en) Use of levosimendan for treating erictile dysfunction
GB0126904D0 (en) Treatment of sexual dysfunction
GB0111037D0 (en) Treatment of sexual dysfunction

Legal Events

Date Code Title Description
DISC Decisions on discontinuance of the proceedings (taken after the publication of the particulars of the applications)